Roles of Epigenetics in Cardiac Fibroblast Activation and Fibrosis
Overview
Biophysics
Cell Biology
Molecular Biology
Authors
Affiliations
Cardiac fibrosis is a common pathophysiologic process associated with numerous cardiovascular diseases, resulting in cardiac dysfunction. Cardiac fibroblasts (CFs) play an important role in the production of the extracellular matrix and are the essential cell type in a quiescent state in a healthy heart. In response to diverse pathologic stress and environmental stress, resident CFs convert to activated fibroblasts, referred to as myofibroblasts, which produce more extracellular matrix, contributing to cardiac fibrosis. Although multiple molecular mechanisms are implicated in CFs activation and cardiac fibrosis, there is increasing evidence that epigenetic regulation plays a key role in this process. Epigenetics is a rapidly growing field in biology, and provides a modulated link between pathological stimuli and gene expression profiles, ultimately leading to corresponding pathological changes. Epigenetic modifications are mainly composed of three main categories: DNA methylation, histone modifications, and non-coding RNAs. This review focuses on recent advances regarding epigenetic regulation in cardiac fibrosis and highlights the effects of epigenetic modifications on CFs activation. Finally, we provide some perspectives and prospects for the study of epigenetic modifications and cardiac fibrosis.
Decoding the regulatory roles of circular RNAs in cardiac fibrosis.
You Q, Yu J, Pan R, Feng J, Guo H, Liu B Noncoding RNA Res. 2025; 11:115-130.
PMID: 39759175 PMC: 11697406. DOI: 10.1016/j.ncrna.2024.11.007.
Epigenetic Regulation in Myocardial Fibroblasts and Its Impact on Cardiovascular Diseases.
Komal S, Gao Y, Wang Z, Yu Q, Wang P, Zhang L Pharmaceuticals (Basel). 2024; 17(10).
PMID: 39458994 PMC: 11510975. DOI: 10.3390/ph17101353.
Wu X, Lee Y, Lau Y, Au K, Tse Y, Ng K Pharmaceuticals (Basel). 2024; 17(8).
PMID: 39204134 PMC: 11357512. DOI: 10.3390/ph17081030.
Khalaji A, Mehrtabar S, Jabraeilipour A, Doustar N, Rahmani Youshanlouei H, Tahavvori A Ther Adv Cardiovasc Dis. 2024; 18:17539447241253134.
PMID: 38819836 PMC: 11143841. DOI: 10.1177/17539447241253134.
Progress and prospect of nanotechnology for cardiac fibrosis treatment.
Gaytan S, Beaven E, Gadad S, Nurunnabi M Interdiscip Med. 2023; 1(4):e20230018.
PMID: 38089921 PMC: 10712437. DOI: 10.1002/INMD.20230018.